Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Three Experts Discuss the Use of Cetuximab in Head and Neck Cancers

November 30th 2014

Cetuximab is the only FDA-approved EGFR inhibitor for the treatment of squamous cell carcinoma of the head and neck.

Dr. de Groot Discusses Altiratinib as Potential Treatment for Glioblastoma

November 17th 2014

John F de Groot, MD, nuro-oncologist, MD Anderson Cancer Center, discusses the efficacy of the novel c-MET inhibitor altiratinib in glioblastoma.

Dr. Stupp Discusses NovoTTF With Temozolomide in Glioblastoma

November 16th 2014

Roger Stupp, MD, Professor of Oncology, University of Zürich; Chairman, Department of Oncology and Cancer Center, University of Zürich Hospital, Zürich, Switzerland, discusses the interim analysis of the EF-14 trial, which compared NovoTTF-100A together with temozolomide versus temozolomide alone in patients with newly diagnosed glioblastoma multiforme (GBM).

Immunotherapeutic Strategies in Head and Neck Cancer

November 7th 2014

Both HPV-positive and -negative head and neck cancers are "outstanding candidates for immunotherapeutic strategies," said Andrew G. Sikora, MD, PhD, Baylor College of Medicine, at the 2014 Chemotherapy Foundation Symposium.

Dr. Brose Discusses Lenvatinib and Sorafenib in Differentiated Thyroid Cancer

November 2nd 2014

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses the rapidly changing treatment landscape for patients with differentiated thyroid cancer.

Dr. Sosa Discusses Molecular Testing in Thyroid Cancer

November 2nd 2014

Julie A. Sosa, MD, MS, professor of surgery and medicine, chief of endocrine surgery, Duke University, discusses molecular testing for thyroid cancer.

Novel NGS Test May Enhance Diagnosis and Management of Indeterminate Thyroid Nodules

November 2nd 2014

A next-generation sequencing assay has shown promise as a new tool to aid in the diagnosis and treatment of indeterminate thyroid nodules.

Next-Generation Sequencing Effectively Detects Cancer in Thyroid Nodules

November 2nd 2014

The ThyroSeq v2 next-generation sequencing assay was highly accurate at diagnosing cancer in thyroid nodules with follicular neoplasm or those suspected of follicular neoplasm cytology.

Vitamin D Levels Predict Hypocalcemia After Thyroid Cancer Treatment

November 1st 2014

Preoperative vitamin D deficiency is associated with postoperative symptomatic hypocalcemia in patients with thyroid cancer undergoing total thyroidectomy plus central compartment neck dissection.

Novel Therapeutic Target Identified in Aggressive Thyroid Cancers

November 1st 2014

In vivo models for two aggressive thyroid cancers have shown that downregulation of miR-30a-5p leads to overexpression of LOX, a target which appears amenable to treatment with β-aminopropionitrile fumarate.

New Assay Effectively Detects Circulating BRAFV600E in Patients With Papillary Thyroid Cancer

November 1st 2014

The detection of BRAFV600E in patients with papillary thyroid cancer using a blood-based assay was shown to be feasible in a cohort of patients undergoing thyroidectomy.

Dr. Ganly on a Postoperative Nomogram for Predicting Cancer-Specific Mortality in MTC

November 1st 2014

Ian Ganly, MD, PhD, from Memorial Sloan Kettering Cancer Center, discusses the development of a postoperative nomogram for predicting cancer-specific mortality in MTC.

Dr. Bible Discusses the Promise of Pemetrexed in Follicular Thyroid Cancers

November 1st 2014

Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the promise of pemetrexed and carboplatin as a potential treatment option for patients with follicular cell-derived thyroid cancers.

ATA Highlights New Thyroid Cancer Research

October 31st 2014

The impact of RAI on long-term outcomes, potential combination strategies, molecular profiling, and novel therapeutics for patients with thyroid cancer were among some of the topics highlighted at the 2014 ATA Annual Meeting.

Dr. Busaidy on the Association Between THST and Improved Outcomes

October 31st 2014

Naifa L. Busaidy, MD, associate professor, MD Anderson Cancer Center, discusses the results of a cooperative study that investigated the association between long-term thyroid hormone suppression therapy and improved outcomes in patients.

Moderate THST Improves Outcomes in Differentiated Thyroid Cancer

October 31st 2014

Long-term moderate thyroid hormone suppression therapy is associated with improved outcomes in patients with differentiated thyroid cancer.

Dr. Nucera Discusses the Role of RNA in Thyroid Cancer

October 31st 2014

Carmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer

Disease-Related Variables Predictive of Outcomes With Sorafenib in DTC

October 31st 2014

Numerous disease-related variables could serve as prognostic and predictive factors for treatment outcomes with sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer.

Dr. Dadu on Reducing MTC-Related Diarrhea With CASAD

October 31st 2014

Ramona Dadu, MD, from the MD Anderson Cancer Center, discusses the results of a pilot study that examined the efficacy of CASAD, a natural clay, to reduce medullary thyroid cancer-related diarrhea.

Dr. Cohen Discusses the Challenges of Treating Medullary Thyroid Cancer

October 30th 2014

Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses the challenges of treating Medullary Thyroid Cancer (MTC).

NEXT PAGE
PREVIOUS PAGE